SPOTLIGHT -
Should RCC Patients With Nodal Disease be Reclassified?
A study shows stage III renal cell carcinoma patients with nodal disease may need to be reclassified.
Checkpoint Inhibitors Highly Active in Metastatic RCC
A study shows RCC patients overall response rate did not decline from the first‐line to the fourth‐line of IO therapy.
Do Some Prostate Cancer Therapies Raise Patients’ Risks for Bladder Cancer?
Treatment for prostate cancer with external beam radiotherapy was found to be associated with an increased risk for development of bladder cancer when compared with radical prostatectomy.
When to Order an MRI in the Initial Evaluation and Management of Prostate Cancer
This article summarizes the current role of multiparametric MRI in the diagnosis, risk assessment, and treatment of prostate cancer.
Does Frailty Predict for Complications After Bladder Cancer Surgery?
Measures of frailty and comorbidity failed to offer predictive information regarding complications in patients with bladder cancer undergoing radical cystectomy.
The Link Between Apalutamide and QOL in Non-Metastatic CRPC
New research in Lancet Oncology confirms previous studies in this population on the addition of apalutamide to androgen deprivation therapy.
Radical Prostatectomy Plus Radiotherapy Extends OS in Prostate Cancer
A study in Cancer found a lower risk of prostate cancer–specific death and improved overall survival when patients were treated with this combination.
Differentiating Benign Renal Tumors From Chromophobe RCC
A radiographic measure may help clinicians distinguish between benign renal oncocytoma and chromophobe renal cell carcinoma.
Partial Nephrectomy Linked to Improved OS in T1a RCC
A study shows T1a RCC patients have improved overall survival when receiving partial nephrectomy compared with radical nephrectomy.
Are Stromal Cells Mediating Response to Immunotherapy in Bladder Cancer?
New research suggests that immune resistance in urothelial cancer may be mediated by stromal cells, which act as a source of EMT-related gene expression.
ANO7 Gene Linked to Aggressive Prostate Cancer
By elevating the expression of ANO7, a potential prostate cancer susceptibility gene, it may be possible to predict disease severity and outcome.
Do Dose-Dense Neoadjuvant Chemo Regimens Improve Responses in Bladder Cancer?
A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients.
Complications of Androgen Deprivation Therapy in Men With Prostate Cancer
This article summarizes the key side effects associated with ADT for the treatment of prostate cancer and discusses strategies to optimize management.
Nuclear Pore Proteins May Be Effective Anti-Cancer Targets for Prostate Cancer
A particular gatekeeper-the nuclear pore protein called POM121-traffics molecules that increase tumor aggressiveness in prostate cancer.
New Therapeutic Target for Clear Cell RCC?
ZHX2 has been identified as a possible new therapeutic target for clear cell RCC patients.
Blood Biomarker May Help Identify Those at Increased Risk for RCC
Concentrations of KIM-1 in the blood may predict for renal cell carcinoma up to 5 years prior to diagnosis.
Post-Surgical Relapse Patterns in High-Risk Non–Clear Cell RCC
Cross-sectional, long-term imaging is shown to be important for patients with high-risk resected non–clear cell RCC.
Locoregional Recurrence Rates Vary Based on Several Factors in Bladder Cancer
A meta-analysis identified several factors that are correlated with locoregional recurrence in patients with nonmetastatic muscle-invasive bladder cancer.
Is Marital Status Associated With Bladder Cancer Outcome?
An existing body of literature shows that marital status and related social support are connected with disease outcomes.
FDA Approves Iobenguane I 131 for Rare Adrenal Gland Tumors
Intravenous Iobenguane I 131 has been approved to treat unresectable, locally advanced, or metastatic pheochromocytoma.
Obesity Linked With Increased Risk of Certain Subtypes of RCC
A nested case-control study found that the association between obesity and RCC varies depending on subtype.
Photodynamic Diagnosis of Bladder Cancer With Oral 5-ALA Is Feasible, Safe
TURBT with fluorescent light source using oral 5-ALA is well tolerated in non–muscle-invasive bladder cancer.
Poorer Survival, Higher Costs With Trimodal Therapy in Bladder Cancer
Patients with muscle-invasive bladder cancer who underwent trimodal therapy had significantly poorer survival than those who underwent radical cystectomy alone.
Sorafenib as Effective, Safe in Elderly RCC Patients as in Younger Ones
PFS, tumor response, and safety outcomes were similar in patient cohorts under age 75 vs those 75 years of age and older.
IKCC, German Cancer Society Issue Consensus Statement on RCC With Bone Mets
The statement emphasizes strategies for multidisciplinary care, and proposes an algorithm for clinical management of bone metastasis in RCC.
A Call for Better Screening for Hereditary Renal Cell Carcinoma
More than 20% of patients with non–clear cell RCC had a germline mutation, and half of this group could benefit from direct systemic therapy.
Genomic Analyses Reveal Dozens More Prostate Cancer Susceptibility Loci
A large genomic analysis identified more than 60 new prostate cancer susceptibility loci, including one locus significantly associated with early onset.
Metabolomic Analysis May Provide Non-Invasive Bladder Cancer Surveillance
A new study identified several metabolites and metabolic indicators as potential biomarkers for recurrence risk in non–muscle-invasive bladder cancer.
FGFR Inhibitor Shows Promise in Advanced Urothelial Carcinoma
A phase II study found that the FGFR inhibitor erdafitinib yields a good response rate and was well tolerated in patients with urothelial carcinoma and FGFR alterations.
Olaparib/Abiraterone Combo Improves PFS in CRPC
The combination of the PARP inhibitor olaparib and abiraterone offered improved efficacy in patients with metastatic castration-resistant prostate cancer, but at what cost?
